Suppr超能文献

多瓣膜病的病理生理学和治疗。

Pathophysiology and management of multivalvular disease.

机构信息

Cardiology Department, CHU Saint-Pierre, Université Libre de Bruxelles, 322 rue Haute, B-1000, Brussels, Belgium.

Quebec Heart &Lung Institute, Department of Medicine, Laval University, Chemin Sainte-Foy, Quebec City, QC, G1V 4G5, Canada.

出版信息

Nat Rev Cardiol. 2016 Jul;13(7):429-40. doi: 10.1038/nrcardio.2016.57. Epub 2016 Apr 28.

Abstract

Multivalvular disease (MVD) is common among patients with valvular disease, and has a complex pathophysiology dependent on the specific combination of valve lesions. Diagnosis is challenging because several echocardiographic methods commonly used for the assessment of stenosis or regurgitation have been validated only in patients with single-valve disease. Decisions about the timing and type of treatment should be made by a multidisciplinary heart valve team, on a case-by-case basis. Several factors should be considered, including the severity and consequences of the MVD, the patient's life expectancy and comorbidities, the surgical risk associated with combined valve procedures, the long-term risk of morbidity and mortality associated with multiple valve prostheses, and the likelihood and risk of reoperation. The introduction of transcatheter valve therapies into clinical practice has provided new treatment options for patients with MVD, and decision-making algorithms on how to combine surgical and percutaneous treatment options are evolving rapidly. In this Review, we discuss the pathophysiology, diagnosis, and treatment of MVD, focusing on the combinations of valve pathologies that are most often encountered in clinical practice.

摘要

多瓣膜病(MVD)在瓣膜病患者中较为常见,其病理生理学较为复杂,取决于特定的瓣膜病变组合。由于几种常用于评估狭窄或反流的超声心动图方法仅在单瓣膜病患者中得到验证,因此诊断具有挑战性。关于治疗时机和类型的决策应由多学科心脏瓣膜团队根据具体情况做出。应考虑多种因素,包括 MVD 的严重程度和后果、患者的预期寿命和合并症、联合瓣膜手术相关的手术风险、多个瓣膜假体相关的长期发病率和死亡率风险,以及再次手术的可能性和风险。经导管瓣膜治疗在临床实践中的应用为 MVD 患者提供了新的治疗选择,如何结合手术和经皮治疗选择的决策算法正在迅速发展。在这篇综述中,我们讨论了 MVD 的病理生理学、诊断和治疗,重点介绍了在临床实践中最常遇到的瓣膜病变组合。

相似文献

1
Pathophysiology and management of multivalvular disease.
Nat Rev Cardiol. 2016 Jul;13(7):429-40. doi: 10.1038/nrcardio.2016.57. Epub 2016 Apr 28.
2
Assessment of Complex Multi-Valve Disease and Prosthetic Valves.
Heart Lung Circ. 2019 Sep;28(9):1436-1446. doi: 10.1016/j.hlc.2019.04.024. Epub 2019 Jun 21.
3
Transcatheter Aortic Valve Replacement in Patients With Multivalvular Heart Disease.
JACC Cardiovasc Interv. 2020 Jul 13;13(13):1503-1514. doi: 10.1016/j.jcin.2020.03.052.
4
The Complexities of Multivalvular Disease Management: Navigating Known Unknowns and Unknown Unknowns.
JACC Cardiovasc Interv. 2024 Aug 26;17(16):1932-1935. doi: 10.1016/j.jcin.2024.07.010.
5
Transseptal transcatheter mitral valve-in-valve: A step by step guide from preprocedural planning to postprocedural care.
Catheter Cardiovasc Interv. 2018 Sep 1;92(3):E185-E196. doi: 10.1002/ccd.27128. Epub 2017 May 30.
10
Transcatheter Tricuspid Valve-in-Valve and Valve-in-Ring Implantation for Degenerated Surgical Prosthesis.
JACC Cardiovasc Interv. 2019 Aug 12;12(15):1403-1412. doi: 10.1016/j.jcin.2019.05.029. Epub 2019 Jul 17.

引用本文的文献

1
Epidemiology of Valvular Heart Disease in Asia Pacific Region.
JACC Asia. 2025 May 3;5(6):718-43. doi: 10.1016/j.jacasi.2025.03.011.
2
Characteristics and Problems of Rheumatic Heart Disease in Indonesia: The Ina-RHD Multicenter Study.
JACC Asia. 2025 Sep;5(9):1171-1183. doi: 10.1016/j.jacasi.2025.03.010. Epub 2025 May 13.
3
Multivalvular vs single-valve infective endocarditis: a systematic review and meta-analysis.
Future Cardiol. 2025 Feb;21(2):113-121. doi: 10.1080/14796678.2025.2457898. Epub 2025 Jan 30.
5
Recovery of left ventricular function after surgery for aortic and mitral regurgitation with heart failure.
Int J Cardiol Cardiovasc Risk Prev. 2024 Sep 2;23:200329. doi: 10.1016/j.ijcrp.2024.200329. eCollection 2024 Dec.
6
Degenerative Mitral Stenosis-Diagnostic Challenges and Future Directions.
Rev Cardiovasc Med. 2022 Oct 18;23(10):354. doi: 10.31083/j.rcm2310354. eCollection 2022 Oct.
7
Treatment of Moderate Functional Mitral Regurgitation during Aortic Valve Replacement: A Cohort Study.
Rev Cardiovasc Med. 2023 Jan 3;24(1):5. doi: 10.31083/j.rcm2401005. eCollection 2023 Jan.
10
Prognostic Impact of Residual Moderate Mitral Regurgitation Following Valve-in-Valve Transcatheter Aortic Valve Implantation.
Braz J Cardiovasc Surg. 2023 Oct 27;39(1):e20230012. doi: 10.21470/1678-9741-2023-0012.

本文引用的文献

1
The clinical challenge of concomitant aortic and mitral valve stenosis.
Acta Cardiol. 2016 Feb;71(1):3-6. doi: 10.2143/AC.71.1.3132091.
3
First-in-Man Experience of a Novel Transcatheter Repair System for Treating Severe Tricuspid Regurgitation.
J Am Coll Cardiol. 2015 Dec 8;66(22):2475-83. doi: 10.1016/j.jacc.2015.09.068. Epub 2015 Oct 11.
4
Multiple valve disease - assessment, strategy and intervention.
EuroIntervention. 2015 Sep;11 Suppl W:W14-6. doi: 10.4244/EIJV11SWA3.
5
Tricuspid regurgitation diagnosis and treatment.
Eur Heart J. 2017 Mar 1;38(9):634-638. doi: 10.1093/eurheartj/ehv487.
6
Ventricular Function Before and After Surgery for Isolated and Combined Regurgitation in the Young.
Ann Thorac Surg. 2015 Oct;100(4):1383-9. doi: 10.1016/j.athoracsur.2015.06.009. Epub 2015 Aug 14.
7
Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis.
Heart. 2015 Sep;101(17):1395-405. doi: 10.1136/heartjnl-2014-307120. Epub 2015 Jun 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验